dasatinib-related bleeding “mild and manageable”

Reactions 1259 - 4 Jul 2009 Dasatinib-related bleeding "mild and manageable" While dasatinib therapy is associated with bleeding, the episodes are "usually mild and manageable", according to a US research team. Most episodes involve gastrointestinal (GI) haemorrhages and advanced-phase chronic myelogenous leukaemia (CML) and thrombocytopenia appear to be risk factors. The research team evaluated 138 patients receiving dasatinib for CML in phase I and II trials. Bleeding (≤ grade 3) occurred in 23% of patients. The median time to bleeding onset was 6 weeks (range 0.5–38). Bleeding occurred in 12%, 31% and 35% of patients treated in the chronic, accelerated and blast phases, respectively. The majority of bleeding episodes (81%) involved the GI tract. Multivariate analysis showed that thrombocytopenia and CML phase (accelerated and blast phases versus chronic phase) were associated with an increased risk of bleeding (risk ratios of 1.002 and 1.69, respectively). The researchers suggest that close monitoring for signs of bleeding is warranted in advanced-phase CML patients receiving dasatinib. Quint´ as-Cardama A, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 115: 2482-2490, No. 11, 1 Jun 2009 801148502 1 Reactions 4 Jul 2009 No. 1259 0114-9954/10/1259-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved

Upload: leliem

Post on 16-Mar-2017

215 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Reactions 1259 - 4 Jul 2009

Dasatinib-related bleeding"mild and manageable"

While dasatinib therapy is associated with bleeding,the episodes are "usually mild and manageable",according to a US research team. Most episodes involvegastrointestinal (GI) haemorrhages and advanced-phasechronic myelogenous leukaemia (CML) andthrombocytopenia appear to be risk factors.

The research team evaluated 138 patients receivingdasatinib for CML in phase I and II trials. Bleeding(≤ grade 3) occurred in 23% of patients. The median timeto bleeding onset was 6 weeks (range 0.5–38). Bleedingoccurred in 12%, 31% and 35% of patients treated in thechronic, accelerated and blast phases, respectively. Themajority of bleeding episodes (81%) involved the GItract. Multivariate analysis showed thatthrombocytopenia and CML phase (accelerated andblast phases versus chronic phase) were associated withan increased risk of bleeding (risk ratios of 1.002 and1.69, respectively).

The researchers suggest that close monitoring forsigns of bleeding is warranted in advanced-phase CMLpatients receiving dasatinib.Quintas-Cardama A, et al. Bleeding diathesis in patients with chronic myelogenousleukemia receiving dasatinib therapy. Cancer 115: 2482-2490, No. 11, 1 Jun2009 801148502

NEUAUFLAGE Dasatinib - medonline€¦ · Dasatinib, November 2015 Ziel der Publikation Die Reihe ArzneimittelPROFIL fasst die aktuell verfügbare wissenschaftliche Evi-denz zu einer

Manageable Switch

AUSTRALIAN PRODUCT INFORMATION – SPRYCEL (DASATINIB) · AUSTRALIAN PRODUCT INFORMATION – SPRYCEL® (DASATINIB) 1 NAME OF THE MEDICINE Dasatinib 2 QUALITATIVE AND QUANTITATIVE

Phase II Study of Dasatinib in Advanced Sarcomas SARC009

Dasatinib (BMS-354825), a Dual SRC/ABL Kinase Inhibitor ......Dasatinib (BMS-354825), a Dual SRC/ABL Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane, and

Making Maintenance Manageable

Dasatinib-Induced Pulmonary Arterial Hypertension Treated ...Case Report Dasatinib-Induced Pulmonary Arterial Hypertension Treated with Upfront Combination Therapy Makoto Nishimori

Sprycel, INN: dasatinib - Europa

CML - tumorzentrum.at€¦ · Dasatinib 2 100 mg/d oder oder unzureichendes Ansprechen 3, Resistenz, Intoleranz Mutationsanalyse 4 Dasatinib 100 mg/d Nilotinib 2 x 300 mg/d Dasatinib

Making it Manageable

Einfluss von Dasatinib auf die Expansion, Zytotoxizität ... · 3.1.2 Dasatinib erhöht nicht die Gesamttodesrate von NK-Zellen ..... 29 3.1.3 Expansion der NK-Zellen unter Dasatinib

Dasatinib, nilotinib and standard-dose imatinib for the first-line … · Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: